XML 48 R2.htm IDEA: XBRL DOCUMENT v3.24.1
Pay vs Performance Disclosure
 12 Months Ended
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Pay vs Performance Disclosure        
Company Selected Measure Name organic revenue growth      
Named Executive Officers, Footnote For each of the years presented in the table, our CEO was Jonathan J. Mazelsky. Our other NEOs were Brian P. McKeon (2020-2023), James F. Polewaczyk (2020-2023), Michael J. Lane (2020-2023), Tina Hunt (2021-2023), and Sharon E. Underberg (2020).      
Peer Group Issuers, Footnote The peer group TSR set forth in the table utilizes the S&P 500 Health Care Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation S-K included in our Annual Report on Form 10-K for the year ended December 31, 2023. The measurement period to calculate the S&P 500 Health Care Index TSR begins as of market close on December 31, 2019 and ends on December 31, 2020, 2021, 2022 and 2023 as applicable. The calculation of the S&P 500 Health Care Index TSR assumes an investment of $100 in the S&P 500 Health Care Index as of the close of trading on December 31, 2019, and assumes dividends, if any, were reinvested.      
PEO Total Compensation Amount $ 11,519,309 $ 9,788,388 $ 9,065,021 $ 7,038,175
PEO Actually Paid Compensation Amount $ 22,675,198 (13,754,140) 28,210,038 34,873,879
Adjustment To PEO Compensation, Footnote The table below provides a summary of deductions and additions made from the summary compensation table (SCT) total for our CEO to calculate the “compensation actually paid” to our CEO. The amount has been calculated in accordance with Item 402(v) of Regulation S-K and the dollar amount of the “compensation actually paid” does not reflect the actual amount of compensation earned or paid to the CEO during the applicable year. There were no equity award forfeitures nor dividends or other earnings paid on stock or option awards in any of the applicable years and thus no adjustments are reflected for such events in the table below.
Year2023
($)		2022
($)		2021
($)		2020
($)
Summary Compensation Table for CEO11,519,309 9,788,388 9,065,021 7,038,175 
DeductionsGrant date value of Stock Awards granted during fiscal year as reported in the SCT 2,187,697 1,937,696 1,500,029 1,125,087 
Grant date value of Option Awards granted during fiscal year as reported in the SCT 6,562,842 5,812,593 4,499,229 3,375,000 
AdditionsFair value as of year end of outstanding and unvested equity awards granted during fiscal year 10,282,274 6,449,518 8,858,781 11,773,116 
Change in fair value (comparing year end to the end of prior fiscal year) of equity awards granted in a prior fiscal year that are outstanding and unvested at year end 6,759,528 (15,299,044)13,640,628 18,767,155 
Fair value of equity awards on vest date for equity awards granted and vested during fiscal year — — — — 
Change in fair value (comparing the vesting date to the end of the prior fiscal year) of equity awards granted in a prior fiscal year that vested during the fiscal year 2,864,627 (6,942,713)2,644,866 1,795,521 
Compensation Actually Paid to CEO22,675,198 (13,754,140)28,210,038 34,873,879 
      
Non-PEO NEO Average Total Compensation Amount $ 3,313,564 2,782,492 2,848,443 2,311,502
Non-PEO NEO Average Compensation Actually Paid Amount $ 6,133,478 (3,411,052) 8,009,991 10,522,557
Adjustment to Non-PEO NEO Compensation Footnote The table below provides a summary of deductions and additions made from the average summary compensation table (SCT) total for our other NEOs to calculate the average “compensation actually paid” to our other NEOs. The amount has been calculated in accordance with Item 402(v) of Regulation S-K and the dollar amount of the average “compensation actually paid” does not reflect the actual average amount of compensation earned or paid to the other NEOs during the applicable year. There were no equity award forfeitures nor dividends or other earnings paid on stock or option awards in any of the applicable years and thus no adjustments are reflected for such events in the table below.
Year2023
($)		2022
($)		2021
($)		2020
($)
Summary Compensation Table Average for other NEOs$3,313,564 $2,782,492 $2,848,443 $2,311,502 
DeductionsGrant date value of Stock Awards granted during fiscal year as reported in the SCT662,577 462,560 399,899 300,042 
Grant date value of Option Awards granted during fiscal year as reported in the SCT1,425,027 1,387,558 1,199,793 900,003 
AdditionsFair value as of year end of outstanding and unvested equity awards granted during fiscal year2,418,164 1,520,657 2,340,819 3,139,539 
Change in fair value (comparing year end to the end of prior fiscal year) of equity awards granted in a prior fiscal year that are outstanding and unvested at year end1,606,730 (3,973,866)3,751,718 5,913,551 
Fair value of equity awards on vest date for equity awards granted and vested during fiscal year— — — — 
Change in fair value (comparing the vesting date to the end of the prior fiscal year) of equity awards granted in a prior fiscal year that vested during the fiscal year882,624 (1,890,216)668,703 358,010 
Average Compensation Actually Paid to Other NEOs$6,133,478 $(3,411,052)$8,009,991 $10,522,557 
      
Compensation Actually Paid vs. Total Shareholder Return
3298534884359
      
Compensation Actually Paid vs. Net Income
3298534884414
      
Compensation Actually Paid vs. Company Selected Measure
3298534884465
      
Total Shareholder Return Vs Peer Group
3298534884359
      
Total Shareholder Return Amount $ 212.56 156.23 252.16 191.43
Peer Group Total Shareholder Return Amount 143.18 140.29 143.09 113.45
Net Income (Loss) $ 845,000,000.0 $ 679,100,000 $ 744,800,000 $ 581,800,000
Company Selected Measure Amount 0.09 0.07 0.16 0.12
PEO Name Jonathan J. Mazelsky      
Additional 402(v) Disclosure
Pursuant to Section 953(a) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(v) of Regulation S-K, we are required to provide annual disclosure of certain information to describe the relationship between “compensation actually paid” to our CEO and other NEOs and our financial performance. For further information regarding our compensation philosophy and how executive compensation aligns with performance, refer to the discussion under “Compensation Discussion and Analysis” beginning on page 74.
The following pay versus performance table sets forth information required by Item 402(v) of Regulation S-K, including: (i) the total compensation earned by our CEO (as reported on our Summary Compensation Table), (ii) the “compensation actually paid” to our CEO (calculated in accordance with Item 402(v) of Regulation S-K), (iii) the average of the total compensation earned by our other NEOs (derived from our Summary Compensation Table), (iv) the average “compensation actually paid” to our other NEOs (calculated in accordance with Item 402(v) of Regulation S-K), (v) our net income and (vi) our organic revenue growth rate, in each case, for each of the covered fiscal years of 2020, 2021, 2022 and 2023, as well as our cumulative total shareholder return and that of the S&P 500 Health Care Index (our pay versus performance peer group) over such period.
Equity values used to determine the deductions and additions set forth in the tables in notes (2) and (3) above to calculate “compensation actually paid” for our CEO and average “compensation actually paid” for our other NEOs are calculated in accordance with FASB ASC Topic 718. Adjustments with respect to stock option awards have been made as of each measurement date using the stock price as of the measurement date and updated assumptions (i.e., term, volatility and risk free rates) as of the relevant measurement date in accordance with U.S. GAAP. The methodology used to develop the valuation assumptions as of each relevant measurement date does not differ materially from those disclosed at the time of grant.The measurement period to calculate total shareholder return (TSR) begins as of market close on December 31, 2019 and ends on December 31, 2020, 2021, 2022 and 2023, as applicable. The calculation of TSR assumes an initial investment of $100 as of the close of trading on December 31, 2019, and assumes dividends, if any, were reinvested.
As detailed earlier under “Compensation Discussion and Analysis” beginning on page 74, we seek to create alignment between management and shareholder interests. We do so, in part, by compensating our NEOs primarily with variable and “at-risk” compensation elements. In particular, a majority of the value of our NEOs’ total target direct compensation is in the form of long-term equity awards. As a result, the increase in our stock price during 2023 resulted in “compensation actually paid” for our CEO and average “compensation actually paid” for our other NEOs that was significantly higher than the corresponding total compensation amounts reported in the Summary Compensation Table for 2023.
The following graphs describe the relationship between the annual total compensation actually paid to our CEO, the average annual total compensation actually paid to our other NEOs, the total shareholder return of our stock, the total shareholder return of the S&P 500 Health Care Index, our net income and our organic revenue growth rate, as each is disclosed in the pay versus performance table above.
Pursuant to Item 402(v)(6) of Regulation S-K, we are required to provide a tabular list of at least three, and up to seven, financial performance measures, which in our assessment represent the most important financial performance measures used by us to link compensation actually paid to our NEOs, for 2023, to our performance.
For a description of the financial performance measures and how they factor into our annual performance-based cash bonus program, refer to the discussion under “Financial Performance Factor” beginning on page 88. 		     
Measure:: 1        
Pay vs Performance Disclosure        
Name Organic revenue growth      
Non-GAAP Measure Description For a discussion of how organic revenue growth was used by IDEXX to link “compensation actually paid” to our NEOs in 2023 to our financial performance, refer to the discussion under “Financial Performance Factor” beginning on page 88. Organic revenue growth is a non-GAAP financial measure. Information regarding organic revenue growth and its calculation is provided in Appendix A. While we use a variety of financial performance measures for the purpose of evaluating performance as part of our executive compensation programs, we have determined that organic revenue growth is the financial performance measure that, in our assessment, represents the most important performance measure (that is not otherwise required to be disclosed in the table) used in 2023 to link “compensation actually paid” to the NEOs to the Company’s performance because it is the metric with the highest weighting in the financial performance factor portion of our Executive Incentive Plan.      
Measure:: 2        
Pay vs Performance Disclosure        
Name Earnings per share (diluted)      
Measure:: 3        
Pay vs Performance Disclosure        
Name Operating profit      
Measure:: 4        
Pay vs Performance Disclosure        
Name ROIC      
PEO | Equity Awards, Stock Awards Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 2,187,697 $ 1,937,696 $ 1,500,029 $ 1,125,087
PEO | Equity Awards, Option Awards Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 6,562,842 5,812,593 4,499,229 3,375,000
PEO | Equity Awards Granted During the Year, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 10,282,274 6,449,518 8,858,781 11,773,116
PEO | Equity Awards Granted in Prior Years, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 6,759,528 (15,299,044) 13,640,628 18,767,155
PEO | Equity Awards Granted During the Year, Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 0 0 0
PEO | Equity Awards Granted in Prior Years, Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 2,864,627 (6,942,713) 2,644,866 1,795,521
Non-PEO NEO | Equity Awards, Stock Awards Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 662,577 462,560 399,899 300,042
Non-PEO NEO | Equity Awards, Option Awards Reported Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,425,027 1,387,558 1,199,793 900,003
Non-PEO NEO | Equity Awards Granted During the Year, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 2,418,164 1,520,657 2,340,819 3,139,539
Non-PEO NEO | Equity Awards Granted in Prior Years, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 1,606,730 (3,973,866) 3,751,718 5,913,551
Non-PEO NEO | Equity Awards Granted During the Year, Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 0 0 0
Non-PEO NEO | Equity Awards Granted in Prior Years, Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 882,624 $ (1,890,216) $ 668,703 $ 358,010